GPC3 and metabolic dysfunction-associated steatotic liver disease: However, a more powerful predictive approach based on the measurement of circulating biomarkers to assess the risk of developing HCC in nonalcoholic fatty liver disease (NAFLD) affected livers has been tuned through stratification of patients by age, gender, and the levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II), GPC-3, and adiponectin (AUC = 0.948) [146].